PTC to Announce Fourth Fiscal Quarter and Full Year 2025 Results on Wednesday, November 5th, 2025 Life Science Investing
Telo Genomics Expands Operations with Relocation of Clinical Laboratories to New, Larger Toronto Facility and Provides Board Update Genetics Investing
PTC Delivers New Service Lifecycle Management AI Solutions to Modernize Field Service and the Service Supply Chain Life Science Investing
FDA Approves Guardant360® CDx as Companion Diagnostic for Eli Lilly and Company's Inluriyo for Treatment of ESR1-mutated Advanced Breast Cancer Genetics Investing
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Genetics Investing
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025 Genetics Investing
Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership Genetics Investing
